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Abstract

In vitro protein selection has had major impacts in the field of protein
engineering. Traditional screens assay individual proteins for specific function.
Selection, however, analyzes a pool of mutants and yields the best variants. Phage
display, a successful selection technique, also provides a reliable link between variant
phenotype and genotype. It can also be coupled with high throughput sequencing to
map protein mutations; potentially highlighting vital mutations in variants. We propose
to apply this technique to cancer therapy. RAF, a serine/threonine kinase, is critical for
cell regulation in mammals. RAF can be activated by oncogenic RAS, found in over 30%
of cancers, to drive cancer proliferation. Rigosertib, a benzyl styryl sulfone in phase III
clinical trials for myelodysplastic syndrome (MDS), is an inhibitor of the RAS binding
domain (RBD) in RAF. Phage display can be used to select RAF mutants for RAS binding
affinity, in the presence of Rigosertib. High-throughput sequencing of these variants can
provide a means of anticipating, and mapping resistance to this anti-cancer drug.
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Summary
In vitro protein selection has had major impacts in the field of protein
engineering and analysis. While traditional screens assay individual mutants or
proteins of interest for specific function, selection analyzes a pool of mutants by
subjecting them to a set of conditions that are designed to yield the best variants.
Selection, however, is plagued by the difficulty of accurately identifying the genotypes
of selected variants. Phage display is a successful selection technique that provides a
reliable link between protein and genotype. Ff bacteriophage can display non-native
proteins alongside its coat proteins. This is accomplished by cloning a protein of
interest into the genome of Ff bacteriophage, which results in the display of that protein
on the phage coat. Thus, a single phage links the genotype and phenotype of the protein
that its genome includes. Furthermore, once cloned into a phage genome, a protein can
be diversified to create a mutant library. This library of phage can be selected for
specific function effectively and efficiently. Selected phage can then be characterized via
high throughput sequencing to map vital protein mutations; highlighting mutations
conserved across multiple variants that may be involved with the function of interest.
The coupling of selection and high throughput sequencing can have major
implications for cancer therapy. RAS is a small-GTPase membrane bound protein,
primarily involved with signal transmission in cells. Oncogenic mutations in RAS have
found in over 30% of cancers. RAS oncogenes are involved in signal transduction
pathways that affect cell apoptosis, proliferation, and division, and can initiate or
perpetuate human carcinomas. RAF is a serine/threonine kinase directly downstream
of RAS. RAF is critical for cell growth and regulation in mammals via its role in the
cytoplasmic kinase cascade signaling pathway. Oncogenic RAS has been found to impact
tumor growth through the RAF-mediated pathway. Because RAS is involved in a
number of cellular pathways, drugs that specifically inhibit binding between RAS and
RAF can affect the mutagenic effects of oncogenic RAS without adversely impacting
other vital RAS function in the cell.
Rigosertib, a benzyl styryl sulfone in phase III clinical trials for myelodysplastic
syndrome (MDS), is a small molecule inhibitor of the RAS binding domain of RAF (RBD).
It is possible that RAF may develop a functional resistance mutation that reduces
Rigosertib binding affinity, while retaining RAS binding affinity. By combining phage
display selection of RAF variants, with high-throughput sequencing we can understand
and map RAF resistance to Rigosertib. This information can be used to enhance current
and future cancer therapeutics.
A library of RAF mutants will be successfully displayed on Ff bacteriophage. This
library will then undergo a selection strategy that will procure variants with high
binding affinity to RAS in the presence of Rigosertib. We can infer that these variants
have developed resistance to the anti-cancer drug. Following selection, these variants
will be characterized by high-throughput sequencing, and functional resistance
mutations will be identified. Lastly, selected variants will be tested for functionality in
1

downstream signaling interactions; the development of resistance is not entirely
effective if downstream function is impaired, and signal transduction cannot occur.
Experimental Aim 1: Create library of RAF mutants and confirm phage display by selecting
for mutant binding affinity to RAS
Experimental Aim 2: Use phage display to identify RAF mutants that exhibit resistance to
Rigosertib, while simultaneously retaining binding affinity to RAS
Experimental Aim 3: Test selected mutants for functionality within the RAF-MEK-ERK
pathway
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A. Phage Display
In vitro protein selection has gained ground in the field of protein engineering
and analysis.1 Selection techniques are a better tool than screens for analyzing and
specifying molecular function and efficiency. Screens assay individual mutants or
proteins of interest for specific function, resulting in the identification of the best
protein within the batch. The method of selection, on the other hand, is the analysis of a
pool of variants, or mutants, under a set of selection conditions that yield the most
efficient or functional variants.1 In the past, the difficulty associated with selection
methods was grounded in identifying a realistic and efficient method with which to link
genotype with the yielded proteins.1 Phage display has provided a method with which
to select for specific function and efficiency, while simultaneously providing a reliable
link between protein and genotype. Filamentous phage is used as a base for the display
of peptides and proteins, while containing the desired deoxyribonucleic acid (DNA)
sequence within its genome.2 The method was initially described by Smith in 1985,3 and
has since been utilized to alter the function of polypeptides, and discover novel
properties. It can even be used in conjunction with high throughput sequencing to map
protein mutations, and identify amino acid mutations that are integral to novel protein
function or increased efficiency.4 Phage display follows a simple scheme, as described in
Figure 1. A protein of interest and a substrate are identified.5 The protein and substrate
can represent protein-protein, protein-peptide, or protein-DNA interactions, among
others.2,6 The gene encoding the protein of interest is then inserted into the
bacteriophage genome, and expressed on the phage’s coat proteins.2 Selection (for
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binding, affinity, catalysis, etc.) is completed via washing and elution of phages under
various selection parameters.

Figure 1. Schematic displaying a general
phage display experiment.
A.1. Phage Biology
Ff filamentous Escherichia coli bacteriophage are most commonly used in phage
display.7 These bacteriophages have proven ideal for phage display for a number of
reasons. They are stable in a range of selection parameters. The filamentous phage
genome is relatively small, about 6400 nucleotides, and tolerates insertions in a number
of non-essential/non-coding regions.2,7 The phage does not kill the host cell, and thus
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can replicate in high volumes.2,6 Lastly, the bacteriophage coat can be mutated or
alerted while retaining the phage’s infectivity.2
A.1.1. Structure
The structure and function of Filamentous bacteriophages has been widely
studied. The Ff class of filamentous phage is made up of f1, fd, and M13, which are all fpilus dependent viruses; they use the F conjugative pilus as a receptor.2,6 These
bacteriophages encase a circular, single-stranded, DNA genome in a long protein capsid
cylinder.2,6,7 The phage genome encodes for 11 proteins in total (Figure 2). Two
proteins are involved with phage export, the entire capsid is made up of five coat
proteins, and the other four proteins are minor coat proteins and are used for cell
infection, and phage replication.2
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Figure 2. Ff bacteriophage proteins and functions.
The gene VIII protein (pVIII), the major coat protein, is comprised of 50 amino
acids and composes the protein cylinder that encapsulates the phages single-stranded
DNA (ssDNA).6 pVIII molecules pack tightly, overlapping like fishscales,2 to form a righthanded helix. Phage particles have a fixed diameter of 6.5 nm, and their length is
determined by their genome size.2 For example, the length of the 6400 nucleotide
ssDNA Ff phage particle is 930 nm,6 while the length of a smaller variant of with 221
nucleotides is 50 nm.8 Thus, genome insertions result in longer phages. In order to
contain these insertions, the phage elongates by producing more pVIII proteins.7 The
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length of an insertion must, however, be considered since longer phages can be prone
to instability and breakage (Figure 3).2

Figure 3. Gene insertions into the phage genome elongate the
phage particle. The phage accomplishes this by producing and
incorporating more pVIII capsid proteins in the major coat.
One end of the phage contains about 5 copies of both the gene VII and gene IX
proteins (pVII and pIX).6 pVII, 33 residues, and pIX, 32 residues, are located at the end
of the phage where the genome’s packaging signal is located.6 Phage assembly begins at
this end of the phage, and both proteins are vital for phage formation.2
The other end of the phage house 5 copies of both the gene III and gene VI
proteins (pIII and pVI).6 pIII, 406 residues, is composed of three glycine-rich regions
(Figure 4).6 Two of the regions are required for cell infection; one is required for
binding to the cell membrane, and the other is necessary for the transportation of phage
genome into the cytoplasm and insertion of phage proteins into the cell membrane.6
The third glycine-rich region is necessary for the formation of stable phage
particles.6,9,10 This third pIII region, along with pVI, 112 residues, interacts with pVIII to
form the second end of the phage particle.11 Both of these proteins are involved in the
detachment of newly formed phage from host cell membranes.2 Not much else is known
7

about the function of pVI, except that it seems to form a complex with pIII,12,13 and that
it degrades in the absence of pIII.11

Figure 4. Structure of pIII and
fusion points for display on phage.
The CT domain (residues 257406) is embedded in the phage
particle, while the N domains (N1;
residues 1-68, and N2; residues
87-217) are exposed. Glycine-rich
linker regions connect the three
domains (Gly1 and Gly2).
Positions 198 and 249 are typical
positions for protein of interest
gene fusion. Image adapted from
Ref. 2.
A.1.2. Cell Infection
The f-pilus dependency of Ff bacteriophages, indicates that these phages
typically infect bacteria cells that express and display F pili on their cell membranes.2,6
These pili exhibit normal assembly-retraction cycles,6 in which they continuously
extend upon assembly and retract upon disassembly.2 Binding of the phage pIII to an F
pilus retracts the pilus and brings the phage into close proximity of the cell surface.6
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Once the phage is close to the cell membrane, another domain within pIII binds to a coreceptor Tol protein (the F pilus is the receptor).2 Interaction of the pIII end of the
phage with the host cell’s Tol proteins is vital for phage infection.14,15 Upon infection,
the phage’s single stranded DNA genome is translocated into the cell’s cytoplasm, while
the phage coat proteins are embedded within the cell membrane, where they await
phage replication.2,6
A.1.3. Phage Replication
Phage replication can be separated into three distinct stages.
First, the phage’s single-stranded DNA is converted into a double-stranded
molecule called replicative form (RF) via the host cells RNA and DNA polymerases and
topoisomerase.2 The bacteria’s replicative enzymes and molecules replicate the original
viral single-stranded DNA, + strand, to form a complimentary – strand, producing the
RF. The RF is then transcribed into mRNA. Lastly, the cellular ribosomes then translate
the mRNA into proteins. These proteins are transported to the cell membrane, where
they are embedded for phage release.
The second stage of the replication process is initiated by the gene II protein
(pII).2 The + strand of the RF is nicked by pII, producing a free 3’ end in the DNA strand.
DNA polymerase then elongates the + strand DNA, beginning at the 3’ end and using the
– strand as template. DNA polymerase is further assisted by pII, which unwinds the +
strand through a rolling circle mechanism, thus, allowing DNA polymerase to fully
replicate the DNA strand.2 Lastly, the new + strand is recircularized by pII, and
converted into another RF molecule.
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The third stage of replication is initiated by the gene V protein (pV). In the early
stages of infection/replication the concentration of pV is low, and single-stranded DNA
particles are converted into RF with little inhibition.2 As more RF is accumulated, and
the concentration of expressed phage proteins increases, the presence of pV affects the
replication cycle. pV is a binding protein which surrounds and binds newly synthesized
single-stranded DNA + strands before they can be converted to RF. This is a vital step,
as the double-stranded RF cannot be packaged into phage. These pV/single-strand
complexes are then transported to the cell membrane,2 where minor and major coat
capsid proteins have been embedded. The pV/single-strand complex is oriented such
that the DNA begins to protrude from the cell. At this point, pV binding proteins release,
and are replaced by the capsid proteins. As the final capsid proteins are assembled onto
the new phage, the replication process of the phage terminates, and the newly
synthesized phage particle is released from the host cell.
A.2. Display Proteins
Display on phage is achieved via fusion of the gene encoding the protein of
interest to phage protein genes. The most commonly used coat proteins used for phage
display are pVIII and pIII. pVIII, the protein that composes the phage cylinder, is used
less frequently than pIII. Two factors contributing to this are: the protein can only
display short sequences of (6-8) residues (longer sequences can prevent the packaging
of phage molecules, likely due to interactions with pIV),2 and the protein will display on
all copies of pVIII in a phage (this can cause avidity effects with multiple binding
interactions and make it difficult to accurately characterize function of the protein of
interest). There is a limitation to the use of pVIII; a requirement of short sequences
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reduces the number of target peptides that can be analyzed. Recent work has extended
the applicability of pVIII phage display. pVIII proteins have been engineered to display
large polypeptides at numbers sufficient enough to produce an 100-fold improvement
in detection of fusion proteins.16 Other work has developed successful fusion of
proteins of interest to an artificial major coat protein (pVIII mimic) at the C-terminus
which expands the range of proteins that can be displayed on pVIII (as opposed to the
N-terminus, which is generally the location of insertion on pVIII).17
The common site of insertion for proteins of interest is the pIII gene.5 This gene
codes for the expression of five copies of pIII on the end of the virion. Unlike pVIII, pIII
can tolerate large insertions while retaining the phage’s infectivity.2 pIII is made up of
three domains (N1, N2, and CT), and two glycine-rich linker regions. The N domains are
located in the exposed N-terminal, and serve as contact points for interaction between
the phage and ligands. The CT domain is located in the C-terminal, which is buried in
the phage, and is linked to the assembly of the virus.2 The protein of interest can be
inserted into the pIII gene at the end of the N2 domain (residue 198) or to the glycinerich linker region that is near the CT domain (residue 249). Both fusion locations have
successfully displayed proteins on pIII in filamentous phage.18,19
A.3. Phage Library Construction
A.3.1. Phage Vectors
Once a display protein has been chosen as the fusion site for a protein of interest,
it must then be cloned into the gene and incorporated into the phage genome for
display. This is accomplished with a display vector. Some vectors are commercially
available, and are ready for use in various experiments. For other proteins, however,
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that have not been displayed on phage, a vector must be constructed and its
functionality must be tested. Two major factors in display vector construction are
vector type, and valency.1,2 Display vectors are predominately of two forms: phage
vectors and phagemid vectors (Figure 5).1,2,20 Valency refers to the number of foreign
proteins that a phage displays.21 Multivalent, or polyvalent, phage are those that display
more than one copy of the foreign protein of interest per phage particle. Monovalent
phage predominately display one protein of interest per phage particle. Confirmation of
display on phage is the final step in the construction of a vector. Vectors must
successfully be able to facilitate display of the protein of interest, such that it is both
displayed and functional.
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Figure 5. Comparison of phage and phagemid vector cloning for pIII display. Target
protein sequences are inserted before gene III. Both vector methods carry a phage
replication origin (Ff) to permit phage genome replication. Phagemid vectors also
carry a plasmid origin of replication, and an antibiotic resistance marker. Helper
phage facilitates viral protein expression, but is packaging-deficient and does not
compete with the phagemid genome during assembly. In this experiment,
monovalent phage display is preferred as it reduces the avidity effects that plague
polyvalent display. Image adapted from Ref. 2.
A.3.1.a.

Phage and Phagemid Vectors

Proteins displayed using vectors based directly within the Ff phage sequence –
those incorporated directly into the coding sequence for either pIII or pVIII – are
considered phage vectors. Phage vectors typically result in the display of the protein of
interest on all copies of the coat protein, and, thus, are only used in polyvalent
display.3,22 This phage vector display method has been used to analyze small
peptides,23–25 and even functional enzymes.26 Polyvalent display, however, features
some drawbacks. Polyvalent display prevents the identification of high-affinity
clones.18,24 The use of polyvalent phage display to analyze the binding affinity of peptide
libraries to a (beta)-endorphin antibody recovered sequences that were weakly binding
relative to the original starting sequence.24 Similarly, attempts to use polyvalent phage
display to select for high-affinity mutants of human growth hormone (hGH) from
among a library of mutants with large binding affinity variations (over 20-fold) were
unsuccessful.18 These studies found that polyvalent phage display results in multi-point
attachment to ligands during selection, as a result of the number and proximity of
displayed proteins of interest.2,18,24 This multi-point attachment, thus, makes weakbinding clones appear as if they have high affinity, an effect known as avidity (the
strength of a receptor-ligand complex of N receptor-ligand interactions).2 Additionally,
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phage vector display is complicated by the difficulty of cloning directly within the phage
genome without disrupting important promoters, genes, or other genome structural
components.2 For these reasons, monovalent phage display is preferred for
experiments seeking to select mutants with the highest affinities.2
Monovalent display was developed to account for, and avoid, potential avidity
effects associated with polyvalent display.18,19 Phagemid vector display has been shown
to produce monovalent display phages that can be used to sort between low- and highaffinity mutants.18,19 Phagemid vector display, unlike phage vector display, does not
feature the introduction of the gene of interest directly into the phage genome. The
displayed protein gene is, instead, fused to the pIII or pVIII genes in a plasmid under the
control of a weak promoter.2,22 The plasmid typically contains: a plasmid origin, a phage
replication origin (Ff origin), and an antibiotic resistance marker. Thus, this plasmid
contains the sequence necessary for the production of the pIII-protein fusion and for
packaging of single stranded vector into phage particles, but is incapable of encoding
viral genes.18 Thus, the phagemid vector technique requires the infection of E. coli
containing the phagemid with helper phage that is packaging-deficient, it has a
compromised Ff origin.1,2 The helper phage introduces the genome necessary for the
cell to express the viral proteins necessary for phage replication. Because the cells will
express all of the wild-type proteins and the fusion protein encoded in the phagemid,
the extruded phage particles will contain both proteins.2 Additionally, the deficient
packaging of the helper phage genome ensures that most of the phage particles will
contain the more stable phagemid genome, thus preserving the genotype-phenotype
link.2 Typically, the wild-type proteins, including wild-type pIII, will be expressed in
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excess relative to the fusion protein. This results in <10% of the phagemid particles
displaying only one copy of the pIII-fusion protein, <1% displaying two copies, and the
rest of the particles displaying solely wild-type pIII.1,2,22 The phage particles displaying
only wild-type proteins will be eluted during selection, and, therefore, do not affect
selection for binding affinity.2,22 Similarly, the small percentage of phage particles that
display two copies of pIII-fusion protein is statistically insignificant upon multiple
rounds of selection.22
Not only does monovalent display, and, as an extension, phagemid vector
construction mitigate any potential avidity effects, they also feature additional
advantages.22
The first advantage of monovalent display is the conservation of phage
infectivity. The majority of pIII proteins on phagemid constructed phage are wild-type,
thus these phage are able to infect host cells with nearly identical rates to wild-type
phage.22 Polyvalent display of pIII proteins, on the other hand, results in display phage
that are less infective than wild-type phage.22
Another major advantage of phagemid display vectors is that they can be used to
also freely express the protein of interest for biochemical analysis and sequencing.2,22
The addition of an amber stop codon (TAG) between the inserted gene and the pIII gene
in the phagemid facilitates the controlled free expression of the protein of interest.19
Expression of vectors containing the amber stop codon within E. Coli strains that
suppress the stop codon, amber-suppressors, allows for protein translation through the
stop codon, resulting in pIII-fusion proteins.2,22 Vectors of interest (ones that have gone
through a selection process, perhaps) can then be transformed into non-suppressor E.
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Coli strains, resulting in the expression of the protein of interest (not fused to pIII).2,22
This method has been used to effectively display and express high levels of non-phagelinked Fabs and hGH without additional phage genome manipulation.19,27
A.3.1.b.

Vector Display Confirmation

Confirmation that a newly constructed phagemid vector, or phage vector,
actually displays the protein of interest is vital. Phage enzyme-linked immunosorbent
assays (ELISA) is a successful method for establishing the functional display of a protein
on phage. In the case that display cannot be confirmed, modifications to the fusion gene,
vector type, or display protein used must be considered.2
A.3.2. Library Construction
Once a display vector has been constructed and confirmed for a protein, the
protein can then be diversified. Protein diversification allows for the analysis of effects
that various mutations have on protein folding, structure, and activity. Libraries with
diversities of approximately 1010 are reasonably constructed,28,29 with some methods
reaching even larger orders of magnitude. Diversification can aim for complete
randomization, allowing for mutations among all amino acids and across the entire
gene sequence. Other diversification methods can produce biased or incomplete mutant
libraries, which can be composed of specific amino acid subsets or limited to specific
locations within the gene sequence.
Regardless of which library construction method is used, the ability to create
large libraries of mutant proteins allows for the analysis of, and insight into, the
interactions in receptor-ligand complexes. Phage display is a valuable protein
engineering tool as it allows for successful evaluation of a large library of protein
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variants, in the range of 108, as previously discussed. Traditional screening methods are
unable to evaluate nearly as many variants, typically limited to 10-100, due to time and
material constraints.
A.3.2.a.

Oligonucleotide-directed Mutagenesis

Site-directed mutagenesis specifies mutation locations within a gene sequence,
as opposed to completely random diversification. This method of mutagenesis features
the replacement of specific codons in the gene sequence with degenerate codons that
can encode for more than one amino acid.28 These degenerate codons are made up of
mixtures of nucleotides at different positions in the codon’s three-nucleotide sequence.
For example, the codon NNS is able to encode for all amino acids (where N = any
nucleotide, and S = C or G).30 Because site-directed diversification requires the use of
synthetic DNA, and synthetic DNA composition can be altered, facile control of diversity
is achievable. For example, alteration of the design of the degenerate codons will dictate
the focus and breadth of the library’s diversity. For complete diversification of a
sequence, hard randomization, the use of degenerate codons that encode for all amino
acids, is used. Alternatively, tailored randomization restricts the degenerate codons to
those, which only encode for specific amino acid subsets. Lastly, soft randomization, a
more restrictive model, limits degenerate codon variation and biases the mutations to a
predetermined sequence.28
Oligonucleotide-directed mutagenesis is a simple method for constructing sitedirected mutant libraries as described in Figure 6.28 The method can be utilized to
conduct hard randomization, tailored randomization, or soft randomization. The
general scheme for oligonucleotide-directed mutagenesis remains follows the same
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general protocol, regardless of the type of degenerate codon design.28 A template
plasmid, containing the gene of interest, is first prepared for diversification.
Transformation of the template plasmid into an E. Coli dut –/ung – strain, like CJ236,31
purifies the plasmid into a single-stranded form that has a significant amount of
thymine bases replaced by uracil.28 The synthetically designed oligonucleotide,
containing the desired mutations, then anneals to bases preceding and following the
desired mutation region. This oligonucleotide then serves as a primer for a DNA
polymerase, which replicates a complementary strand to the template plasmid. A DNA
ligase then ligates the replicated strand into a circular, double-stranded DNA. The
resulting double-stranded DNA is not entirely complementary; the oligonucleotide
region containing the mutation does not match the template. The introduction of the
double-stranded DNA into an E. Coli ung – strain results in the preferential replication of
the new mutagenic DNA strand.28,31,32 The higher the purity of a template, the more
efficient the oligonucleotide mutagenesis is. Efficiency can range from >50%, to >80%
depending on template purity.28
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Figure 6. Schematic displaying oligonucleotide-directed mutagenesis. a) A synthetic
oligonucleotide is annealed to a single-stranded DNA template that has a significant
amount of thymine bases replaced by uracil (ss-DNA). The oligonucleotide contains
a degenerate codon, and is designed to encode mutations (*). b) A double-stranded
DNA (CCC-dsDNA) is synthesized by polymerase and ligase. c) The CCC-dsDNA is
then transformed into E. coli cells where it is replicated to either the mutant or wildtype sequence. Image adapted from Ref. 28.
A major limitation of oligonucleotide mutagenesis is the fact that it is far from
100% efficient, meaning that libraries constructed using this method will contain wildtype proteins. In cases where the wild-type protein exhibits high affinity for binding to
the target, the wild-type proteins displayed on phage will be selected for alongside
mutant proteins.28 Thus, it is imperative that mutant libraries constructed via
oligonucleotide mutagenesis are purified of the wild-type protein. This can be
accomplished by rendering the template inactive. An inactive template permits the
construction of mutant libraries, retaining the functionality required for
oligonucleotides to bind to the template strand, but does not allow for the expression of
the wild-type protein encoded in the template. The incorporation of stop codons within
the desired mutated region of the template sequence achieves this.28,33 Translation of
19

the stop codon incorporated template sequence results in truncated proteins. Because
they are no longer translated as complete, pIII-fused proteins they cannot be displayed
on phage. The inactive template still serves as the wild-type genome, yet can no longer
interfere with selection.28 In general, templates that contain at least one stop codon per
target region will likely be rendered inactive.
A.3.2.b.

In vitro DNA Recombination

Another robust library construction method is the use of in vitro DNA
recombination in directed evolution. Directed evolution is an in vitro simulation of
natural Darwinian evolution. A protein of interest is run through iterative rounds of
mutation, selection, and screening. Each round is akin to a generation, or another
representative period of time, as in Darwinian evolution. This method allows for the
production of mutants with specific properties.34,35
Stemmer reported the first use of In vitro DNA recombination as a method for
evolution.36,37 DNA shuffling, as Stemmer called it, incorporates a low rate of point
mutations within recombination of related sequences of the template.34 Other In vitro
DNA recombination methods have followed Stemmer’s DNA shuffling. These include
random priming recombination,38 and Staggered extension process (StEP).39
In vitro DNA recombination has proven successful in a number of applications.
Stemmer initially utilized DNA shuffling to improve drug resistance.36,37 Others have
used the method to improve and alter various protein characteristics and functions. The
thermostability of enzymes has been generated and improved by recombination
random mutagenesis and selection.40–42 Additionally, the folding and solubility for
single-chain antibody fragments,43 and the green fluorescent protein were improved.44
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While this library construction method has proven successful in the optimization
and analysis of protein function, it does feature drawbacks. One of its major limitations
is a result of the method’s logic. Because In vitro DNA recombination requires that the
“best,” or most optimized, sequence be selected and then further mutated, it does not
allow for the discovery of other successful mutations. Those mutants can only be
discovered in separate recombination experiments; in which they are found to be the
“best” mutant.34 This is a seemingly small limitation, yet can result in the loss of vital, or
optimal, mutant discoveries.
A.3.2.c.

Other Methods

Other methods for diversification of a mutant library have been described.2
These include but are not limited to: the oligo cassette method,45 recursive polymerase
chain reaction (PCR),46 oligo-splinted assembly,47 error-prone PCR,48 and the use of PCR
with randomized primers.49 Other methods for phage display library construction
involve collections of genes, as opposed alterations to single genes (cDNA libraries,50
and antibody V-region libraries,51 for example). Choosing a method for a specific
experiment depends on a few factors. First, the type of mutagenesis must be
considered. Random mutagenesis can lead to novel function discoveries, while sitedirected mutagenesis allows for the analysis of the impact that specific positions, or
mutations have on function. Second, the target region for diversification must be
defined and considered. If the mutagenesis of an entire gene is desired, it will require a
different method to mutagenesis that aims to contain mutations within a defined
region. Lastly, the efficiency of a method must be weighed against its accuracy, faster
methods may not necessarily have more accurate results, and vice-versa.
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A.3.3. Selection
A.3.3.a.

General Approach

Once a library of mutant proteins has been constructed and displayed on phage,
the library population must be sorted by binding affinity. This stage in phage display is
called selection, and results in the optimization of protein binding to a specific target.
Generally, selection will allow for the separation of tight binders, or “fit” binders, from
non-binders or weakly binding variants. Consecutive rounds of successful selection
yields the emergence of a single clone, or set of clones, that have relatively optimal
binding affinities.3,20
A.3.3.b.

Methods

Selection methods all follow a general idea, the separation of “good” binders,
those that retain or have developed high binding affinity to the target relative to a
standard like wild-type affinity, from non-functional or weak binders. The type of
selection method, however, depends on the mechanism of binding that is being
analyzed, or optimized. In general, selection can be separated into two methods:
immobilization of the displayed protein, or binding of the protein within solution.20
Additionally, selection conditions must be stringent enough to allow for the retention of
fit mutants and the extraction of other variants from the mutant pool. These conditions
must also, however, allow for the recovery of fit variants in order to enable further
selection rounds and final analysis.20 Therefore, a selection strategy must also facilitate
pairing with an efficient and effective elution strategy.
A.3.3.b.1.

Immobilization
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The phage target can be immobilized onto a solid support, thus rendering the
pIII-fusion protein : target interaction immobile. The general mechanism follows as
such: the target (protein, molecule, ligand, etc.) is covalently attached to the solid
support, then the phage library, in the presence of buffer, is introduced into the system
inducing interaction, and finally the mutant variants that do not bind are washed away
and those that do are eluted for further analysis.20 The solid state target can select for fit
variants in one of two ways. Variants can be selected for binding affinity to a substrate
covalently attached to the solid support. Thus, only variants with a relatively high
binding affinity will remain in the system after subsequent washing. In the case that
catalysis optimization is the goal, another setup can be utilized. All variants can be
attached to the solid support, where they are introduced to a substrate, and then
catalysis can result in cleavage of fit variants from the solid support. Upon which
washing of the system would elute fit variants, while less-fit variants remain attached to
the support.5
Elution of directly immobilized phage typically follows one of two general
schemes. In the situation where selection conditions are designed to immobilize phage
based on binding affinity to the solid support, elution aims to dissociate the phage from
the binding target, or to dissociate the target, with the attached phage, from the stable
support itself.20 Phage dissociation from target can be induced by alteration of pH levels
to extremes or addition of denaturants; phage infectivity can be retained after exposure
to extreme conditions.2 Alternatively, binding targets can be covalently attached to solid
supports via specific tags, or engineered cleavage sites (cloning specific amino acid
chains, or binding sites into a protein is an example of engineering). Attachment to solid
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support can be cleaved at these sites upon the incorporation of specific molecules or
conditions. For example, thrombin can be added to a solution to cleave an engineered
thrombin site on a binding target protein.20
If selection aims to optimize the catalytic function of a protein, as previously
described, the elution conditions focus on collection of catalytically active variants. For
catalytic processes that involve cleavage, selection and subsequent elution can be
accomplished by inhibiting cleaving function during the selection stage, and then
inducing cleavage as an elution strategy. Pedersen et al. were able to optimize the
enzyme staphylococcal nuclease (SNase) for the catalysis of DNA cleavage by utilizing
the immobilization method, and eluting variants that had successfully cleaved from the
solid support.5 The activity of the nuclease was inhibited by control of Ca2+ levels; SNase
does not cleave its substrate in the absence of Ca2+. Following selection, elution was
accomplished through the introduction of Ca2+, which detached fit variants from the
solid support by inducing cleavage.
A.3.3.b.2.

Solution Binding

Phage library variants can also be selected via binding in a solution and
subsequent capture by a solid support (i.e. an affinity matrix). This method can reduce
the potential avidity effects of polyvalent phage, because interaction with a target in
solution does not have the same intramolecular effects as binding to targets on a solid
support.20 On a solid support, as previously discussed, a polyvalent phage will initially
bind to a single target, but will undergo multiple binding events as a result of target
proximity the multiple displayed proteins present on a polyvalent phage particle.
Solution binding can still facilitate multiple binding events, however, the likelihood of
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these subsequent binding events is not increased to the degree that binding on a
surface does. This is because each target molecule is independent, and binding does not
inherently bring the phage closer to other targets.
Elution strategies for solution bound phage are similar to those for phage
selected with the immobilization strategy. Generally, elution strategies aim to break the
link between the phage and the binding target, or the affinity matrix. The introduction
of basic or acidic conditions, at levels that the phage can tolerate (which are typically
extreme for most other molecules or organisms), is a typical technique for
accomplishing this. For example, hydrochloric acid (HCl) and triethylamine are typical
reagents.2
A.3.3.b.3.

Selection Conditions

The first round of selection, typically, segregates functional variants from nonfunctional variants.20 This initial step is focused on producing a resultant library that is
diverse, but contains only functional variants. Further rounds of selection aim to obtain
the variants with the highest levels of function. Thus, the stringency of selection
conditions will increase to remove low affinity variants. Methods for increasing
stringency include longer washing times, increased number of washings, the addition of
denaturants,52 increased temperatures or the addition of competitive binders or
ligands.53 The increased stringency results in the selection of more and more optimal
variants, with the final selection aimed at isolating the “best” variant from a specific
library.
B. High-throughput Sequencing.
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While phage display is an effective and efficient method for selecting protein
variants with specific functions and affinities, it does not address the issues associated
with the analysis of the selected variants. Traditionally, mutational analysis was the
primary method with which mutant variants of a protein were examined. Traditional
scanning of mutants does have its drawbacks.4 Originally, mutants were cloned,
expressed, and purified in preparation for assays and further analysis. Phage display, a
method which directly and accurately links phenotype to genotype, reduces the need
for purification of individual protein variants.4 The requirements of Sanger sequencing,
however, still restricted the number of total variants that could be analyzed to a few
thousand. Recent work in high-throughput sequencing, such as combinatorial
scanning,54 and short-read Illumina sequencing,4 has substantially expanded the
volume of variants that can be assessed and sequenced in a reasonable period of
time.55–57 For example, combinatorial “quantitative saturation (QS) scanning” enabled
effective and efficient assessment of the interaction between human growth hormone
(hGH) and its receptor (hGHR).54 High-throughput sequencing, coupled with phage
display selection can be used to map resistance of protein mutants to antibiotics or
anticancer drugs.
B.1. Short Read Illumina sequencing
The principle behind Illumina’s high-throughput sequencing method is that a
DNA template strand is broken into smaller fragments, and then the bases of those
fragments are identified as each section of the entire sequence is re-synthesized as
described in Figure 7. The DNA to be sequenced is extracted and then fragmented into a
collection of short segments. These segments are then simultaneously sequenced via
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Illumina’s sequencing reactions. The resulting sequences, or reads, are then
reassembled in comparison to a reference genome. In the case that a reference genome
is unavailable, or does not exist, the segments can be reassembled via de novo
sequencing methods.58,59

Figure 7. Illumina high throughput sequencing scheme. 1) Multiple DNA sequences
are extracted from selected phage. 2) Sequences are fragmented. 3) Each set of
fragments is labelled with a tag. 4) Fragments are simultaneously sequenced. 5)
Fragments separated by tag. 6) Each set of sequencing reads is compared to a
reference sequence.
High-throughput sequencing of an entire library of DNA (genomes extracted
from a phage display library, for example) can be similarly sequenced. The above
method is simply run in parallel for each sequence of interest. This is accomplished by
27

attaching a specific known barcode sequence to each DNA fragment originating from a
specific original sequence. The fragments are all pooled and sequenced simultaneously,
and the barcode sequences are used to distinguish fragments. Each set of fragments is
then reassembled, based on a reference genome or via de novo sequencing. This
sequencing technique can produce large amounts of sequencing data, with small,
measurable margins of error.4,58,59
B.2. Application and Results
Fowler et al. used high-throughput sequencing to successfully investigate the
binding of the human Yes-associated protein 65 (hYAP65) WW domain to its cognate
peptide ligand for upwards of 600,000 hYAP65 mutants.4 The hYAP65 WW domain was
displayed on the surface of T7 bacteriophage, and mutant variants were selected for
binding affinity to the cognate peptide, attached to a solid support via beads. The WW
domain library varied, or mutated, 33 residues within the domain, and consisted of 99
varied bases. The input variant library, and the libraries after three and six rounds of
selection were sequenced via short-read Illumina sequencing. The sequence data was
then used to map and compare the three libraries, highlighting the relative abundances
of mutations at specific locations through six rounds of selection (Figure 8).
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Figure 8. Sample high throughput
sequencing maps. Maps display the
frequency of reads of a specific amino
acid mutation at a specific position in
the target protein for the variant library
after zero (initial library), three, and six
three rounds of selection, respectively.
Image adapted from Ref. 4.
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Through the use of high-throughput sequencing, coupled with phage display,
Fowler et al. were able make conclusions about mutations at specific positions within
the sequence that improved protein function. More importantly, the mapping of
sequences obtained via high-throughput sequencing could be used to identify positions
within a gene that are vital for protein function, structure, or folding.4
C. RAS Oncogene
C.1. RAS Structure/Function
Four distinct, yet very homologous, RAS proteins are encoded for in the human
genome. The HRAS, NRAS, and KRAS genes encode HRAS, NRAS, KRAS4A, and
KRAS4B.60 RAS proteins are small-GTPase membrane bound proteins, ~21 kDa, that are
primarily associated with signal transmission in cells by pairing cell surface receptors
with intracellular signaling pathways.1,47 They cycle between active, GTP-bound, and
inactive, GDP-bound, states; acting as ON/OFF switches for cell growth, differentiation
and growth.61 Guanine nucleotide exchange factors (GEFs), which can facilitate the
exchange of GDP for GTP on GTPase proteins, activate RAS by promoting the GTPbound state.60,62 On the other hand, GTPase-activating proteins (GAPs), which
accelerate the hydrolysis of GTP into GDP, promote the formation of the inactive, GDPbound, state.60,62 This GAP mediated inactivation of RAS is the main target of somatic
mutations found in oncogenic RAS variants.60 Mutations in RAS at amino acid positions
G12, G13, or Q61 interfere with the ability of GAP to inactivate GTP-bound RAS. In the
presence of any of these mutations, activated RAS will persist within the cell where it
will signal through various pathways facilitating the transformation of mammalian
cells.60,62
30

RAS carries signals to these pathways by binding proteins, or other ligands, at
the effector domain. Binding at this domain, spanning residues 32-40, is essential for
signal transduction.62 It has been shown that mutations in, or near, this region impair
interaction between RAS and its binding partners.63 RAS has specific binding
interactions at the RAS effector domain with a number of RAS effectors, such as:
phosphatidylinositol 3-kinase (PI3K),64 p120 RAS GAP,65 and RIN1.66
C.2. Oncogenic RAS
RAS genes have been found to have oncogenic function via point mutations (at
amino acid positions 12, 13 and 61, for example),67 and that these mutations occur in
30% of human cancers.62,68 Thus, it has been found that RAS proteins are the most
commonly mutated oncogene in human cancer.61 For this reason, inhibition of RAS
oncogenic activation has major implications in cancer therapy.
The oncogenic activity of the four RAS isoforms (HRAS, NRAS, KRAS4A, and
KRAS4B) has not been completely determined, nor has the issue of whether some
isoforms exhibit unique activity been resolved. On one hand, the isoforms follow a nonrandom distribution within the range of known cancer types.69,70 Mutations in HRAS are
frequently detected in skin, head, and neck tumors. KRAS mutations are associated with
colorectal tumors, and lung and pancreatic carcinomas. Lastly, NRAS mutations are
typically found haematopoietic and lymphoid tissue tumors.60 On the other hand, RAS
isoforms can substitute other isoforms within specific tissues, where they perform the
same function as the oncogenic RAS isoform typically associated with that specific
tissue.60,71 Aberrations from this trend have been discovered; especially when RAS
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isoforms are analyzed in vivo. Thus, it has been difficult to determine the exact
mechanisms and interactions that oncogenic isoforms have within the cell cycle.
Independent of RAS isoform variations, oncogenic RAS has phenotypic effects
across a wide range of typical cell functions. In fact, the contribution of oncogenic RAS
to human malignancies is typically underestimated by the frequency of RAS mutations
found in cancer types.60 Mutations in RAS have a wide impact on cancer function, and
the growth and spread of cancer. Oncogenic RAS can affect the promotion of cell
proliferation, the suppression of cell apoptosis, metabolism, the cell microenvironment,
immune response evasion, and metastasis (Figure 9). All of these are vital mechanisms,
functions, or components of cells. Alterations in any of them can induce cancer, or
tumor growth.
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Figure 9. Cancer-related impacts of oncogenic RAS. Table
adapted from Ref. 60.
C.2.1. Cell Proliferation
A common characteristic attributed to carcinoma is the continual expansion of
cancer cells; that is, the growth of cell population via uncontrolled, or atypical, cell
division. Cell proliferation depends on the interference of appropriate cell response to
mitogenic, and anti-mitogenic, cell signals.60 Since RAS is directly involved in the
transmission of mitogenic signals within a cell, oncogenic RAS is able to promote cell
proliferation via a number of mechanisms. The expression of oncogenic HRAS has been
discovered to push a GO phase-arrested cell, a cell that is in a non-dividing equilibrium
state, toward cell division without stimulus from cell growth factors.72
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Additionally, RAS oncogenes can facilitate cell proliferation by signaling for the
upregulation of various transcription factors, such as: FOS, activating transcription
factor 2 (ATF2), JUN (leucine zipper protein, and ELK1.60 The main mechanism in which
oncogenic RAS mediated upregulation of transcription factors leads to cell
transformation is the expression of cyclin D1, the G1 cyclin; a regulator of cell cycle
progression and a transcription co-regulator. This mechanism is validated by the fact
that mice lacking cyclin-D1 have been found to exhibit resistance to carcinomas and
tumors that are promoted by oncogenic HRAS.73,74
There are other ways in which oncogenic RAS can affect cell proliferation via the
upregulation of pathways that lead to cell division (or other cellular pathways that
affect such pathways) or the downregulation of factors involved with the inhibition of
cell growth. Overall, due to the massive role that RAS plays in the regulation of cell
population it is not surprising that RAS oncogenes have been found in a wide range of
cancers.
C.2.2. Cell Apoptosis
The elimination of, or interference with, signaling pathways that induce cell
apoptosis is a major characteristic of cancer, and the spread of cancer cells. Apoptosis is
a programmed process of cell death that can be initiated by extracellular or intracellular
factors. Typically, apoptosis is a response to high levels of cellular stress, and acts as a
defense mechanism against malignancies.60
Oncogenic RAS erodes apoptotic pathways via the upregulation of anti-apoptotic
factors and downregulation of pro-apoptotic factors. Chin et al. discovered that the RAS
oncogene not only arrests cellular apoptosis pathways, but is also important for tumor
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maintenance.75 The downregulation of oncogenic HRASG12V lead to tumor cell apoptosis,
and subsequent regression of melanomas.75 Similarly, the removal of oncogenic
KRASG12D also caused tumor cell apoptosis, accompanied by the regression of lesions
and malignant tumors.76
C.2.3. Metabolism
As RAS oncogenes induce high levels of cell proliferation, accompanied by the
erosion of apoptotic pathways, the need for cellular building blocks increases to
accommodate the increased rates of growth. In order to proliferate, a cell must
accomplish two tasks. It must generate sufficient energy and produce biomolecules at a
rate that meets proliferation demands.77 Thus, cancer is dependent on metabolic
pathways as they provide the components needed for the construction of new cells, and
provide mechanisms for energy production.
In order to meet these needs of proliferation, cancerous cells will shift from
mitochondrial oxidative phosphorylation (OXPHOS) to aerobic glycolysis.60 Glycolysis
in typical mammalian cells is inhibited by the presence of oxygen, which is used by the
mitochondria to oxidize pyruvate to carbon dioxide and water. Aerobic glycolysis
instead, converts pyruvate to lactate.78 This mechanism allows the cell to recover the
NAD+ required for the cycle repeat.77 This self-sustaining cycle can produce more ATP,
and at a faster rate, than OXPHOS, while also providing metabolic intermediates that
can be used for the production of biomolecules required for cell proliferation.
Oncogenic RAS facilitates aerobic glycolysis through numerous pathways. First,
oncogenic RAS stimulates the shift from OXPHOS to glycolysis in cells via the
upregulation of hypoxia-inducible factor 1α.60 Additionally, oncogenic RAS improves a
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cells ability to transport the glucose necessary for glycolysis by upregulating the
glucose transporter GLUT1.60 Lastly, oncogenic RAS affects the synthesis of
biomolecules by increasing the levels of enzymes associated with the processing of
glycolytic intermediates. Hence, RAS oncogenes play a critical role in the cancercharacteristic metabolic shift that cells undergo.
C.2.4. Cell Microenvironment
As the number of cells in a tumor growth increases, the competition for oxygen
and nutrients among cells also increases. Angiogenesis is the growth of new blood
vessels from pre-existing blood vessels. Angiogenesis within a tumor allows for the
delivery of adequate supplies of oxygen, among other nutrients, to sustain tumor
growth.60 Oncogenic RAS reaches beyond the confines of the cell membrane to impact
the extracellular microenvironment, and induce angiogenesis. It accomplishes this by
upregulating angiogenic growth factors and by changing the composition of the
extracellular matrix, the system of biological molecules that provide structural and
signaling support to cells.60 For example, oncogenic RAS targets vascular endothelial
growth factor A (VEGFA), a promoter of endothelial cell growth and the formation of
blood vessels.79 Additionally, matrix metalloproteinase 2 (MMP2), MMP9 and
urokinase-type plasminogen activator (uPA) are upregulated by RAS oncogenes,
resulting in the removal of physical constraints to angiogenesis.80 The role that
oncogenic RAS plays in the promotion of angiogenesis indicates that RAS does not only
increase tumor growth intracellular, but can also impact the extracellular environment.
C.2.5. Evasion of Immune Response
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Humans have mechanisms within their immune systems that can identify and
defend against cancerous tumor growth. These immune responses are vital components
of the body’s defense against cancer. Tumors that can subvert these response, are able
to grow unimpeded by antitumor immunity pathways, which can lead to metastasis.
RAS oncogenes can provide cells with mechanisms with which to evade immune
responses within the body.60
Oncogenic RAS has been found to suppress the effectiveness of the immune
response via two mechanisms.60 First, RAS oncogenes can reduce the expression of
antigens on cell surfaces, thereby aiding in the cell’s ability to evade detection of
lymphocytes.81 Second, oncogenic activity of RAS can actually overcome immune
response, as opposed to evading them. For example, while patients with some forms of
cancers induced by oncogenic RAS possess T-cells that are specific for antigens formed
by these RAS variants, these lymphocytes are rendered angenic and cannot actually
bind the cancer cells.60
C.2.6. Metastasis
Metastasis is the biological process in which tumor cells spread from the organ
of origin to surrounding organs and tissues. Cancers in this stage are difficult to treat
due to the mobile nature of the tumors, and the sheer number of locations in which
tumors are and can be located. Many tumors that have developed metastatic properties
contain oncogenic RAS variants.60
Metastasis is initiated by local tumor cell invasion. In order for a tumor to enter
this stage, individual tumor cells must develop the ability to detach from the tumor.60
Oncogenic RAS facilitates cancer cell acquisition of this property by affecting
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interactions between cells and the extracellular matrix, and by promoting cell
phenotypes that aid in migration.60 RAS oncogenes are able to reduce cellular adhesion
to the ECM by decreasing the presence of integrins that promote cell linkage to the
ECM.82 Additionally, cells must develop a front-rear asymmetry in order to migrate.60
RAS oncogenic activity is able to induce the structural shifts necessary for a cell to
adopt front-rear asymmetry.60
In order for a cancer to continue through metastasis, cancer cells must be able to
detach from the original tumor and enter the bloodstream. Oncogenic activity of RAS
has been shown to degrade the ECM, and impact the integrity of the basement
membrane in order to promote angiogenesis for cell proliferation. The degradation of
the basement membrane, which is vital for the containment of cancer cells, and the
increase of blood vessels near the tumor aid in a cells progression through the
metastatic process.60 Thus, oncogenic RAS is able to further facilitate the migration of
cancer cells.
C.3. Cancer Therapy via RAS Inhibition
RAS has been shown to facilitate tumor growth through numerous pathways,
and mechanisms. Oncogenic activation of RAS has been commonly found in the
progression of human carcinomas via these pathways.62 Therefore, the inhibition of the
activation or function of RAS oncogenes has been a major focus in cancer therapy.
There have been attempts to completely inhibit the function of RAS.62,83 RAS
function, however, is involved in many cellular processes. For that reason, complete
inhibition or alteration of its function is not ideal. The focus has shifted to cancer
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therapeutics that aim to reduce the effects of oncogenic RAS without completely
abolishing all of its function.62
C.4. RAS and the RAF-MEK-ERK Signaling Pathway
C.4.1. RAF Structure/Function
RAF, a serine/threonine kinase, is critical for cell growth and regulation in
mammals.84 RAF is directly downstream of RAS in signal transduction pathways that
affect cell apoptosis, proliferation, and division.85 Furthermore, oncogenic RAS variants
effectively bind, and activate RAF, resulting in cell processes that promote tumor
growth. RAS oncogenes have been shown to induce tumor-related proliferation in cells
by up-regulating cyclin D1 and down-regulating a cyclin-dependent kinase inhibitor,
p27, through RAF and its signaling pathway.86,87 Additionally, oncogenic-RAS mediated
signaling through RAF results in abnormal apoptotic activity. RAF activation results in
both pro-apoptotic and pro-survival signaling. The balance of these two signaling
effects determines cell action; oncogenic RAS pushes the balance toward pro-survival
signaling, and tumor growth.60,88
Vertebrate genomes encode three RAF genes: A-raf, B-raf, and c-raf-1.84 All three
genes feature three highly conserved regions (CR1, CR2, and CR3) within speciesdependent conserved variable sequences.84 The C1 region contains both an 81 amino
acid sequence (residues 51-131) binding active site, and a zinc-finger component.84 The
binding active site is called the RAS binding domain (RBD), and provides a pocket that
the RAS effector domain uses to bind RAF (Figure 10). The zinc-finger of the CR1 region
has been found to be involved with RAS binding.(Bruder J.T. 1992) The CR2 region
contains many serine and threonine residues that participate in the regulation of RAF
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via phosphorylation/dephosphorylation mechanisms. Together, CR1 and CR2 make up
the regulatory part of RAF proteins, while CR3 contains the catalytic binding domain for
downstream activation.84 RAF mutants with extensions to the amino terminal of the
protein, CR2 region disrupting mutations, alteration of the zinc-finger structure, and
even complete deletion of the CR1-CR2 encoding region,89 are still constitutively active,
and have oncogenic characteristics.84

Figure 10. RAF-RBD contact points with the RAS effector domain. Image
adapted from Ref. 89.
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C.4.2. Overview of Signaling Pathway
RAF is the initial protein involved in the cytoplasmic kinase cascade, a signal
transduction pathway that affects cell proliferation and differentiation (Figure 11).84
The mechanism of this kinase cascade is relatively straightforward. RAF activates the
MAP/ERK protein kinase (MEK), the RAF protein’s only known substrate.84 In turn,
MEK activates the mitogen-activated protein kinase (MAPK, or ERK, extracellularsignal-regulated kinase) which transmits the initial signal to various proto-oncogenic
transcription factors and other protein kinases.90 Cell signal receptors are connected to
the RAF-MEK-ERK pathway via RAS.84

Figure 11. The RAF-MEK-ERK kinase cascade signaling
pathway. Image adapted from Ref. 62.
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C.4.3. RAS Involvement in Pathway
The RAF-MEK-ERK kinase cascade is activated by the binding of RAF by RAS. It
has been shown that the RBD of RAF is crucial for interactions between RAS and
RAF.91,92 RAS signaling relies on a highly conserved mechanism62 that features RAS
protein switch I and switch II regions and the RBD of RAS effector proteins, which
includes over 100 other mammalian proteins in addition to RAF.67,91,93,94 Upon binding,
RAS recruits RAF to the plasma membrane.84,95 At the plasma membrane, in the
presence of co-factors, RAF initiates the cytoplasmic kinase cascade.
Oncogenic activity in this pathway has been linked to malignant transformation
of cells, cancer proliferation, and the evasion of cell apoptosis.95 The RAF-MEK-ERK
pathway participates in the expression of cyclin D1.60 Thus, oncogenic RAS can yield
overexpression of cyclin D1, which is associated with uncontrolled cell growth and
cancer progression, via this pathway. Additionally, the RAF pathway contributes to the
suppression of cell-apoptosis induced by oncogenic RAS. RAS-activated RAF
downregulates prostate apoptosis response 4 (PAR4), a protein that inhibits
transcription and acts to promote apoptosis,96 and upregulates anti-apoptotic factors,
such as BCL-2.97 Furthermore, RAS-activated RAF has been demonstrated to
phosphorylate BCL-2-associated agonist of cell death (BAD), which results in the
inactivation of the BCL-2 family anti-apoptotic factors.98
C.5. Past RAS Targeting Drug Therapies
RAS’ role in eukaryotic kinase pathways positions it as a viable drug target for
inhibition of uncontrollable cell growth, and RAS hyperactivation. Prevention of
productive interactions between RAS and its downstream effectors is, in theory, an
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effective inhibition method.61 This could be achieved by limiting the amount of RAS in
the GTP-bound state, reducing the overall number of RAS proteins in a cell, or directly
blocking protein-protein interactions between RAS and its binding partners.61,67 While
these seem like reasonable inhibition mechanisms, there is an issue with direct RAS
inhibition. Inhibitors that cannot distinguish between wild-type and mutant RAS
proteins would likely result in high levels of toxicity.61 Therefore, inhibition
mechanisms that target the binding domains of specific RAS binding partners, such as
RAF in the case of this experiment, can provide effective RAS inhibition, while reducing
resultant toxicity. This is possible because RAS affects multiple signaling pathways.62 By
targeting a specific RAS/RAF effector interaction, drugs that inhibit binding can affect
the mutagenic effects of oncogenic RAS without adversely impacting other vital RAS
function in the cell.
C.6. Rigosertib
Rigosertib, a benzyl styryl sulfone, is a small molecule inhibitor of the RBD
interactions between RAF and RAS. The drug is currently in phase III clinical trials for
myelodysplastic syndrome (MDS), a type of cancer. Rigosertib binds to the RBDs of a
number of RAS effectors, and limits RAS’ ability to bind to them.67 This in turn reduces
RAF activity, and inhibits the RAF-MEK-ERK pathway (Figure 12). Rigosertib has been
shown to inhibit tumor growth in vitro and limit growth in vivo.67,99
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Figure 12. RAS initiated RAF-MEK-MAPK signaling pathway in the
absence and presence of Rigosertib. Image adapted from Ref. 67.
Rigosertib specifically binds to six proteins: three RAF variants (A-RAF, B-RAF,
and C-RAF), FUBP3, Hsp27, and Hsp73.67 In the RAF protein interactions, Rigosertib
bound similar residues to those which RAS has been found to bind (all of which are
conserved in the RAF family of proteins).67 Based on these studies, Athuluri-Divakar et
al. determined that Rigosertib, in fact, acts as a RAS mimetic and utilizes a similar
binding mechanism for interactions with RAF.
Inhibition of oncogenic RAS activity is a reasonable and effective target for
cancer therapy. Rigosertib does exactly this. By acting as a RAS mimetic, Rigosertib
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inhibits binding between RAF and RAS, thus abolishing function in the RAF-MEK-ERK
kinase cascade. This drug has promising implications for the future of therapeutic
intervention in RAS oncogenic activity, and cancer therapy in general. RAF, however,
may develop mutations that reduce the binding affinity of Rigosertib. In the case that
these mutations also reduce binding function between RAS and RAF, they may not have
oncogenic effects; while Rigosertib will not inhibit RAS and RAF interactions by binding
RAF, the binding interaction between RAS and RAF will still be inhibited by the
mutation. Some mutations may, however, have oncogenic effects. RAF may develop a
mutation that negatively impacts RAF binding by Rigosertib, yet retains the binding
function between RAS and RAF. In this case, RAF will have developed functional
resistance to Rigosertib, and oncogenic RAS could signal through the RAF-MEK-ERK
pathway uninhibited by Rigosertib.
By combining phage display selection of RAF variants, with high-throughput
sequencing of variants selected for binding affinity to RAS in the presence of Rigosertib,
we can provide a method for understanding and mapping RAF resistance to the anticancer drug, Rigosertib. This information can be used to alter the structure of
Rigosertib or its mechanism of binding to anticipate resistance, or for the development
of other therapeutics.
D. Proposed Experiments
Our experiment proposes to pair of the phage display of a library of RAF variants
with high-throughput sequencing of variants selected for functional resistance
mutations to Rigosertib to shed light on potential mechanisms for Rigosertib resistance
in the human organism. An overview of our experiment is described in Figure 13.
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Figure 13. Overview of proposed experiment.
Aim 1: Create library of RAF mutants and use phage display to select for mutant binding
affinity to RAS
Aim 1 will result in a phage displayed library of mutant RAF variants that have
been validated for binding affinity to RAS. A library of RAF variants displayed on phage
will be created, and selected for binding to RAS as described in Figure 14. Previously
characterized effects of specific RAF mutations will also be used to assess successful
library creation. Block et al. have characterized specific amino acid positions found in
the RBD of RAF (residues 51-131) that appear to be critical for RAS/RAF binding.91 This
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data will be compared to the mutant RAF library as an additional validation of
successful library creation, and accurate functionality of the RAF variants.

Figure 14. Schematic displaying Aim 1 selection. The phage displayed RAF variant
library is selected for RAS binding function via biotinylated RAS, which binds to
streptavidin beads. The selected variants are then sequenced and compared to the
input library.
First, RAF must be displayed on phage. The gene encoding the RAF protein will
be fused to the filamentous phage M13 gene encoding pIII in a phagemid vector, and
transformed into E. Coli cells with the addition of helper phage (M13KO7, as previously
described).18 We have decided to fuse RAF to pIII with the phagemid vector method
because it produces phages that exhibit monovalent display. Monovalency is desirable
as it reduces any avidity effects that would result from the display of multiple copies of
RAF on a single phage. Additionally, since phagemid vector construction results in a
larger quantity of wild-type pIII displayed on phage, phage infectivity will be conserved.
Lastly, this method will facilitate biochemical analysis and sequencing of selected
phage; free expression of RAF can be conducted with phagemid vectors. Prior to protein
diversification, successful display on phage will be confirmed with a phage enzymelinked immunosorbant assay (ELISA), a successful and commonly used assay for display
confirmation.( xxref Russel M. Lowman H. B. 2004)
Upon confirmation of display on phage, a library of RAF variants will be created.
The library will be constructed by random mutagenesis within the RBD of wild-type
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RAF. Error-prone PCR, a variation of mutagenic PCR, can be used to introduce nonbiased, random mutations within a desired segment of a target sequence.100 For the
purposes of this experiment, error-prone PCR provides distinct advantages to
oligonucleotide site-directed mutagenesis, and In vitro DNA recombination. We are
aiming to uncover functional mutations within the RAF RBD, and thus desire random
mutagenesis across the entire target region. Oligonucleotide site-directed mutagenesis
specifies mutation locations in the target sequence, and cannot efficiently produce a
library of RAF variants with random RBD mutations. In vitro DNA recombination is
prone to the loss of functional mutations as a result of the method’s concept.
Furthermore, error-prone PCR features a number of additional advantages. Primarily, it
is a simple and efficient method. It closely follows a well understood PCR mechanism,
with slight variations, and can produce target levels of mutagenesis relatively
quickly.100 Furthermore, error-prone PCR can be controlled for specific rates of
mutagenesis.101
Error-prone PCR, as a method of random mutagenesis, takes advantage of the
relatively high error rate of Taq DNA polymerase. In a typical PCR reaction the error
rate is around 10-3 errors per nucleotide.102 The relatively low-fidelity of Taq
polymerase can be further exacerbated by varying the reaction conditions, such as
increasing the concentration of Mg2+ or Mn2+ of the reaction mixture.101 Cadwell et al.
utilized such manipulation of reaction conditions to reach an error rate of about 7 × 103
errors per nucleotide with minimal sequence bias.102 Additional parameters may be
altered in order to increase or decrease this error rate to produce the desired rate of
mutagenesis of the target sequence.100
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For the purposes of this experiment, the aim is to produce a library of mutants
that contain an average of one mutation per variant. This rate of mutagenesis will allow
for the accurate attribution of any potential novel function to a specific amino acid
change. While variants with more mutations might exhibit novel function, it would be
difficult to link novel function to the mutations that caused them. As the RBD, an 80residue region, is composed of more than 200 base-pairs of DNA the error-rate that
Cadwell et al. managed to reach, a frequency of 0.66%±0.13% errors per position, will
be sufficient to guarantee at least one mutation per variant.100
To diversify the RAF gene fused to pIII, error-prone PCR will follow a standard
PCR protocol with vital modifications, as previously described.102 Some of the
modifications that are engineered to increase the mutation rate are: an increased MgCl2
concentration to facilitate the pairing of noncomplementary bases, addition of MnCl2
which increases the polymerases error rate, an increase in dCTP and dTTP
concentrations, and an increase in quantity of Taq polymerase units.
We will confirm that the error-prone PCR method successfully diversified the
RAF gene. The quantity and molecular weight of the product will be confirmed via an
agarose gel embedded with ethidium bromide.100 Lastly, we will confirm achievement
of the desired mutation rate by sequencing a sample of the PCR product. Successful
implementation of this protocol will result in a phage displayed library of RAF mutants
that includes no more than 108 mutants.48
Next, the newly synthesized library must be selected for binding to RAS.
Selection will be achieved by a solution binding technique; active RAS binding RAF
mutants will be collected upon successful binding to wild-type RAS. Solution binding
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was chosen over alternative selection techniques, such as immobilization, because it
decreases the likelihood that multiple binding events occur. This will mitigate collection
of variants that appear to have high binding affinity, but in reality only appear to do so
because of avidity effects.
The wild-type RAS, the substrate in this case, will be prepared for selection via
biotinylation, the process of covalently linking a biotin molecule to a protein, or other
molecule. This process typically does not impede or affect protein function due to the
relatively small size of Biotin. In our experiment, wild-type RAS will be enzymatically
biotinylated. Chemical biotinylation, another major biotinylation method, risks protein
inactivation and low biotinylation yield, while enzymatic biotinylation conserves
protein function and leads to high yields.103 The biotin carboxy carrier protein (BCCP), a
13 amino acid peptide, will be fused to wild-type RAS. This sequence contains a lysine
that is specifically biotinylated by BirA, a biotin ligase found in E. Coli.103,104 The BCCPtagged RAS will be transformed into E. Coli and biotinylated as previously described.104
Successful biotinylation will be verified by ELISA, with absorption at 405 nm directly
proportional to the amount of biotinylated products.104
Upon successful biotinylation of wild-type RAS, the phage library will be
incubated in solution with the biotinylated RAS. Streptavidin-coated magnetic beads
will be added to the solution. Only the RAF variants that retain binding functionality
should bind the biotinylated RAS, and thus only those variants will be attached to the
streptavidin beads. The bound phages will then be removed from the solution by
magnet; the streptavidin-coated beads are magnetic. Any background phage will be
removed by buffer washes, while bound phage will remain bound to the streptavidin
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beads.105,106 The selected phage will then be eluted from the beads by 100mM
triethylamine, a reagent that is not toxic to Ff bacteriophage.2,103
Selection will be monitored by incubation of eluted phage samples in E. Coli cells,
as previously described.20 The cells will be plated, incubated, and then colonies will be
counted. Phage concentration (cfu/ml) will be determined. A minimum of 104 cfu/ml is
expected, as this is the number of phage usually required for growth in a culture.20
Successful selection of RAS binding RAF variants will yield between 104 and 109 cfu/ml.
As a control for this selection, the phage library variants will also be selected for
in the absence of biotinylated RAS. None of the phage variants should be attached to the
streptavidin beads in this trial, if this is not the case then the phage library must be
further analyzed to find the cause of binding, or simply re-constructed.
Following selection, successful binding will be experimentally validated. The
bound phages will then be sequenced, and compared to the input RAF variant library to
control for library biases and other potential artifacts. Finally, mutations that retained
RAS-binding affinity will be identified and compared to recent studies.
For validation of binding after selection, we will monitor a sample of 5-10 of the
selected RAF variants for binding affinity to activated RAS, the GTP-bound state.
Selected RAF mutants will be individually incubated in HeLa cells, treated with DMSO,
with glutathione S-transferase (GST) fused RASG12D bound to glutathione-agarose beads.
The level of binding for each RAF variant will then be determined by immunoblot
analysis. This technique was chosen as it has previously been used to successfully
examine RAF binding to activated RAS.67 GST tagging of proteins is useful as it can be
used to induce immobilization by glutathione, which will allow us to immobilize
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functionally binding RAF variants.107 HeLa cells are a desirable medium for this
experiment as they are a human cell line. The decision to construct the phage library
with phagemid vectors will expedite this experiment; phagemid vectors can be used to
express RAF variants that are not linked to phage via amber (TAG) stop codon
incorporation, as previously described.
Once the selected RAF variant population has been validated for binding to RAS,
it will be sequenced with high-throughput short-read Illumina sequencing techniques,
as previously described.4 The technique requires the isolation of phage library DNA by
phenol-chloroform extraction and precipitation by ethanol. The DNA is then amplified,
purified, and sequenced using a Genome Analyzer IIx, an Illumina product. The input
library will also be sequenced. The populations will then be compared to account for
any artifacts or library biases.
Lastly, mutants that are validated for binding affinity to RAS will then be
compared to prior studies. Block et al. found that mutations at specific locations within
the RBD of RAF reduced RAF/RAS binding affinity (Figure 15).91 Validation of the
library of RAF variants will depend on the mutations found in variants that were
selected for RAS binding. This method will serve as a secondary validation. If any of the
selected variants contain mutations that have been found to reduce binding affinity,
then there are three plausible explanations. First, the less likely explanation, the
findings in previous studies may be incorrect, such that the mutations that have been
found to impede RAF/RAS binding actually do not do so. Second, the much more likely
explanation, it is possible that the creation of the phage library either didn’t successfully
incorporate mutations into the RAF sequence, or that the RAF variants were not
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successfully displayed on the bacteriophage. Third, it is also possible that these mutant
variants contain more than one mutation, and that the additional mutation(s) restored
function in RAF in the presence of the function inhibiting mutation. In either case, these
findings would require troubleshooting and additional analysis; anywhere from resequencing the selected variants to re-constructing the phage library.

Figure 15. RAF mutations with known negative
impacts on RAS binding affinity. This will be used as
an additional validation of the library of RAF mutants.
Variants that bind RAS should not contain any of
these mutations. Image adapted from Ref. 91.
Aim 2: Use phage display to identify RAF mutants that exhibit resistance to Rigosertib
while, simultaneously, retaining binding affinity to RAS
The goal of incorporating Rigosertib as a selection condition is to evaluate
whether the selected RAF variants have developed the novel function of resistance to
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RAS-mimetic cancer therapeutics, primarily Rigosertib. Theoretically, RAF variants, that
have been validated for binding to RAS, that are able to retain binding affinity for RAS in
the presence of Rigosertib will have developed resistance to the cancer drug. These
variants can then be characterized to determine which mutations developed this
resistance in the variant. Identification of functional resistance mutations to Rigosertib
can provide vital insight for future cancer therapy.
Once the phage library of RAF variants has been validated, it will be used to
select for RAF/RAS binding function retaining RAF mutants with developed resistance
to Rigosertib as described in Figure 16. Following selection and purification of these
mutants, they will be characterized by high-throughput sequencing and mapped to
display mutational tolerance and function conservation in the RBD.

Figure 16. Schematic displaying Aim 2 selection strategy. The phage displayed RAF
variant library undergoes two rounds of selection for RAS binding: in the absence
and presence of Rigosertib, the RAS mimetic inhibitor. Both sets of selected mutants
are sequenced, and compared to the input library.
The same phage library, which has already been subjected to two selection trials
(no RAS in the selection conditions, and then with the addition of biotinylated RAS), will
undergo another selection trial. The library must now be selected for RAS binding in the
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presence of Rigosertib, the RAS mimetic. The selection conditions will likely remain
similar to the two other trials, with the exception of the presence of the inhibitory drug.
Due to the mimetic nature of Rigosertib, it is likely that RAF mutations that reduce
RAF/RAS binding affinity will also interfere with the binding of Rigosertib. Variants for
which this is the case will be washed away during selection, as they will not be able to
bind the biotinylated-RAS regardless of their resistance to Rigosertib. This is to be
expected. In fact, these variants are of little interest outside of the role they may play in
validating the mechanism with which Rigosertib binds to RAF. The variants that are
selected, via immobilization by streptavidin beads, will feature mutations that inhibit
Rigosertib binding while retaining RAF/RAS binding function.
Multiple rounds of selection are expected to produce a small subset (50-100
variants) of the original phage library that exhibit high affinity for Rigosertib resistance
and RAS binding. At this point, short-read Illumina sequencing will be used to sequence
these Rigosertib-resistant RAF variants, as previously described.4 This sequence data
will be compared to the data of the pre-selection input library, and the phage selected in
the absence of Rigosertib to control for library biases and artifacts. The sequence data
will also be used to map the prevailing mutations that conferred desired function with a
sequence logo, as previously described (Figure 17).108 These results will highlight vital
mutations for resistance to Rigosertib, thus providing critical insight into potential
mechanisms of resistance that may arise to the use of Rigosertib as a cancer therapy
treatment.
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Figure 17. Sample sequence logo. DNA sequences are aligned and used to create
a sequence logo that highlights conserved nucleotides. This technique will be used
to compare amino acid sequences of selected RAF variants. Image adapted from
Ref. 108.
Aim 3: Test selected mutants for functionality within the RAF-MEK-ERK pathway
The goal of Aim 3 is to determine the downstream functionality of RAF variants
that have gained RAS/RAF functional resistance to Rigosertib. While these variants
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have displayed the ability to resist binding by Rigosertib, and can still be bound by RAS,
they will not have an oncogenic effect if they cannot be activated by RAS, or if they
cannot continue the signal transduction pathway through MEK and ERK. Therefore,
selected variants must be analyzed for functional binding and activation of the other
components of the cytoplasmic kinase cascade.
Selected RAF variants will be tested for functional signaling activity in the RAFMEK-ERK pathway. The MEK-ERK pathway activation assay and subsequent protein
analysis that will be used have been previously described, and conditions are shown in
Table X.67 HeLa cells will be incubated with DMSO (negative control), or Rigosertib and
treated with epidermal growth factor (EGF), which activates RAS.67 The cell lysates will
then be treated with each of the Rigosertib-resistant RAF variants, following variant
expression. Co-immunoprecipitation assays with RAF-specific antibodies and western
blot analyses will be used to determine the level of RAF heterodimerization (a vital
function of wild-type RAF upon RAS activation), the level of phosphorylated-ERK
relative to total ERK, and the level of phosphorylated-MEK relative to total MEK.
Functional signaling RAF variants will readily form heterodimers, and will induce
downstream phosphorylation with little to no change relative to wild-type levels.67
This method was chosen over others, such as the MAP/ERK Kinase Assay,109
because of its similarity to the techniques that we will use to validate binding affinity in
Aim 1. We will not need to obtain many new reagents, or a new cell line. Additionally,
this technique has successfully assessed RAF signaling function in previous studies.
This experiment will identify and characterize mutants that successfully activate
downstream kinases, thus completing signal transduction. These mutants will
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represent fully functional mechanisms for RAF resistance to Rigosertib, and potentially
other RAS mimetic drugs.
D.1. Significance
Successful implementation of this experiment will yield vital information and
insight into the use of Rigosertib, and other RAS mimetic therapeutics, as a cancer
therapy treatment. Pharmacologists and doctors may be able to anticipate resistance to
Rigosertib in vivo and administer treatments that can counter or prevent the
development of RAF resistance. Rigosertib could, for example, be coupled with another
therapeutic cancer drug to anticipate resistance and prevent a second wave of
oncogenic RAF mutants. Furthermore, the experiment may uncover mutants that, in
addition to resisting Rigosertib, successfully activate downstream kinases, thus
completing signal transduction. These mutants will be identified and characterized,
thus improving understanding of the binding mechanism of RAF and RAS, and their
interactions with downstream kinases. The development of additional drug therapies
will be aided by this characterization of oncogenic activity of RAF and RAS in the
cytoplasmic kinase cascade signaling pathway.
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